Jiwon Oh1, Michaela Seigo1, Shiv Saidha1, Elias Sotirchos1, Kathy Zackowski2,3, Min Chen4, Jerry Prince4,5, Marie Diener-West6, Peter A Calabresi1, Daniel S Reich1,6,7,8. 1. Department of Neurology, Johns Hopkins University. 2. Department of Physical Medicine and Rehabilitation, Johns Hopkins University. 3. Motion Analysis Laboratory, Kennedy Krieger Institute. 4. Department of Electrical and Computer Engineering, Johns Hopkins University. 5. Department of Computer Science, Johns Hopkins University. 6. Department of Biostatistics, Johns Hopkins University. 7. Department of Radiology and Radiological Science, Johns Hopkins University. 8. Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke.
Abstract
BACKGROUND: Spinal cord (SC) pathology is common in multiple sclerosis (MS), and measures of SC-atrophy are increasingly utilized. Normalization reduces biological variation of structural measurements unrelated to disease, but optimal parameters for SC volume (SCV)-normalization remain unclear. Using a variety of normalization factors and clinical measures, we assessed the effect of SCV normalization on detecting group differences and clarifying clinical-radiological correlations in MS. METHODS: 3T cervical SC-MRI was performed in 133 MS cases and 11 healthy controls (HC). Clinical assessment included expanded disability status scale (EDSS), MS functional composite (MSFC), quantitative hip-flexion strength ("strength"), and vibration sensation threshold ("vibration"). SCV between C3 and C4 was measured and normalized individually by subject height, SC-length, and intracranial volume (ICV). RESULTS: There were group differences in raw-SCV and after normalization by height and length (MS vs. HC; progressive vs. relapsing MS-subtypes, P < .05). There were correlations between clinical measures and raw-SCV (EDSS:r = -.20; MSFC:r = .16; strength:r = .35; vibration:r = -.19). Correlations consistently strengthened with normalization by length (EDSS:r = -.43; MSFC:r = .33; strength:r = .38; vibration:r = -.40), and height (EDSS:r = -.26; MSFC:r = .28; strength:r = .22; vibration:r = -.29), but diminished with normalization by ICV (EDSS:r = -.23; MSFC:r = -.10; strength:r = .23; vibration:r = -.35). In relapsing MS, normalization by length allowed statistical detection of correlations that were not apparent with raw-SCV. CONCLUSIONS: SCV-normalization by length improves the ability to detect group differences, strengthens clinical-radiological correlations, and is particularly relevant in settings of subtle disease-related SC-atrophy in MS. SCV-normalization by length may enhance the clinical utility of measures of SC-atrophy.
BACKGROUND: Spinal cord (SC) pathology is common in multiple sclerosis (MS), and measures of SC-atrophy are increasingly utilized. Normalization reduces biological variation of structural measurements unrelated to disease, but optimal parameters for SC volume (SCV)-normalization remain unclear. Using a variety of normalization factors and clinical measures, we assessed the effect of SCV normalization on detecting group differences and clarifying clinical-radiological correlations in MS. METHODS: 3T cervical SC-MRI was performed in 133 MS cases and 11 healthy controls (HC). Clinical assessment included expanded disability status scale (EDSS), MS functional composite (MSFC), quantitative hip-flexion strength ("strength"), and vibration sensation threshold ("vibration"). SCV between C3 and C4 was measured and normalized individually by subject height, SC-length, and intracranial volume (ICV). RESULTS: There were group differences in raw-SCV and after normalization by height and length (MS vs. HC; progressive vs. relapsing MS-subtypes, P < .05). There were correlations between clinical measures and raw-SCV (EDSS:r = -.20; MSFC:r = .16; strength:r = .35; vibration:r = -.19). Correlations consistently strengthened with normalization by length (EDSS:r = -.43; MSFC:r = .33; strength:r = .38; vibration:r = -.40), and height (EDSS:r = -.26; MSFC:r = .28; strength:r = .22; vibration:r = -.29), but diminished with normalization by ICV (EDSS:r = -.23; MSFC:r = -.10; strength:r = .23; vibration:r = -.35). In relapsing MS, normalization by length allowed statistical detection of correlations that were not apparent with raw-SCV. CONCLUSIONS: SCV-normalization by length improves the ability to detect group differences, strengthens clinical-radiological correlations, and is particularly relevant in settings of subtle disease-related SC-atrophy in MS. SCV-normalization by length may enhance the clinical utility of measures of SC-atrophy.
Authors: Min Chen; Aaron Carass; Jiwon Oh; Govind Nair; Dzung L Pham; Daniel S Reich; Jerry L Prince Journal: Neuroimage Date: 2013-08-06 Impact factor: 6.556
Authors: G J Nijeholt; E Bergers; W Kamphorst; J Bot; K Nicolay; J A Castelijns; J H van Waesberghe; R Ravid; C H Polman; F Barkhof Journal: Brain Date: 2001-01 Impact factor: 13.501
Authors: Joseph C J Bot; Erwin L A Blezer; Wouter Kamphorst; Geert J Lycklama A Nijeholt; Herman J Ader; Jonas A Castelijns; Klaas Nicolay Ig; Elisabeth Bergers; Rivka Ravid; Chris Polman; Frederik Barkhof Journal: Radiology Date: 2004-09-22 Impact factor: 11.105
Authors: Waqar Rashid; Gerard R Davies; Declan T Chard; Colette M Griffin; Dan R Altmann; Ros Gordon; Raju Kapoor; Alan J Thompson; David H Miller Journal: J Magn Reson Imaging Date: 2006-04 Impact factor: 4.813
Authors: A R Martin; B De Leener; J Cohen-Adad; D W Cadotte; S Kalsi-Ryan; S F Lange; L Tetreault; A Nouri; A Crawley; D J Mikulis; H Ginsberg; M G Fehlings Journal: AJNR Am J Neuroradiol Date: 2017-04-20 Impact factor: 3.825
Authors: Nico Papinutto; Carlo Asteggiano; Antje Bischof; Tristan J Gundel; Eduardo Caverzasi; William A Stern; Stefano Bastianello; Stephen L Hauser; Roland G Henry Journal: J Neuroimaging Date: 2019-09-30 Impact factor: 2.486
Authors: Michael Amann; Simon Pezold; Yvonne Naegelin; Ketut Fundana; Michaela Andělová; Katrin Weier; Christoph Stippich; Ludwig Kappos; Ernst-Wilhelm Radue; Philippe Cattin; Till Sprenger Journal: J Neurol Date: 2016-05-09 Impact factor: 4.849
Authors: Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302
Authors: Nico Papinutto; Regina Schlaeger; Valentina Panara; Alyssa H Zhu; Eduardo Caverzasi; William A Stern; Stephen L Hauser; Roland G Henry Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240
Authors: Burcu Zeydan; Xinyi Gu; Elizabeth J Atkinson; B Mark Keegan; Brian G Weinshenker; Jan-Mendelt Tillema; Daniel Pelletier; Christina J Azevedo; Christine Lebrun-Frenay; Aksel Siva; Darin T Okuda; Kejal Kantarci; Orhun H Kantarci Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-01-22